heartgard 30 plus (ivermectin/pyrantel) chewables each chewable contains 272ug ivermectin and 227mg pyrantel (as embonate salt)
boehringer ingelheim animal health australia pty. ltd. - ivermectin; pyrantel as pyrantel embonate - oral bolus, chewable - ivermectin anthelmintic active 272.0 ug/tb; pyrantel as pyrantel embonate anthelmintic active 227.0 mg/tb - parasiticides - dog | dog - puppy | bitch | castrate | puppy - heartworm - larvae | hookworm - ancylostoma braziliense | hookworm - ancylostoma caninum | hookworm - ancylostoma ceylanicum | hookworm - uncinaria stenocephala | roundworm - toxascaris leonina | roundworm - toxocara canis | ascarid | human intestinal roundworm
risperon
viatris limited - risperidone 1 mg/ml - oral solution - 1 mg/ml - active: risperidone 1 mg/ml excipient: benzoic acid hydrochloric acid purified water tartaric acid - risperidone is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.
reminyl
shire pharmaceuticals limited - galantamine hydrobromide - oral solution - 4 mg/ml - galantamine
avastin concentrate for solution for infusion 100mg4ml
roche singapore pte. ltd. - bevacizumab - infusion, solution concentrate - 25mg - bevacizumab 25mg
perjeta concentrate for solution for infusion 420mg14ml
roche singapore pte. ltd. - pertuzumab - infusion, solution concentrate - 30 mg/ml - pertuzumab 30 mg/ml
avastin concentrate for solution for infusion 400mg16ml
roche singapore pte. ltd. - bevacizumab - infusion, solution concentrate - 400mg - bevacizumab 400mg
promote plus 900 growth regulator
adama australia pty limited - ethephon - soluble concentrate - ethephon organophosphorus active 900.0 g/l - growth regulator
trexject methotrexate (as sodium) 25mg/0.50ml solution for injection pre-filled syringe
link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 25 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.
trexject methotrexate (as sodium) 22.5mg/0.45ml solution for injection pre-filled syringe
link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 22.5 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.
trexject methotrexate (as sodium) 20mg/0.40ml solution for injection pre-filled syringe
link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 20 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.